Table 2 Studies of children with bronchiolitis and post-bronchiolitis, and acute asthma treated with montelukast
From: Update on leukotriene receptor antagonists in preschool children wheezing disorders
| Author | Pros | Cons | |
|---|---|---|---|
| No difference: | |||
| - in length of stay | |||
| Amirav[47] | - in clinical severity score | ||
| - in cytokine levels in nasal lavage fluid | |||
| Bisgaard[48] | No differences in percentage symptom-free days | ||
| No differences: | |||
| Bronchiolitis and post bronchiolitis | Proesmans[49] | - of symptoms and disease-free days and nights | |
| - of n° of exacerbations | |||
| - of n° of unscheduled visits and need of inhaled steroids | |||
| Higher percentage of symptom-free days and nights | |||
| Bisgaard[50] | Reduced daytime cough | ||
| Decreased exacerbations versus placebo | |||
| Kim[51] | Reduced serum eosinophil-derived neurotoxin levels compared with initial levels | ||
| Decreased cumulative recurrent wheezing episodes at 12 months versus placebo | |||
| Harmanci[52] | Reduced oral steroids need | ||
| Acute asthma | Decreased lung index scores and respiratory rate versus placebo | Hospitalization rates not significantly different | |
| Robertson[33] | Reduced healthcare resource use, symptoms, time-off school/parent work | No effect on hospitalization rate, symptoms duration, β2 or steroids use | |
| Bacharier[40] | No difference in symptom free-days, oral steroid, healthcare resource use |
